Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
Clinical trial NCT05141474 · RECRUITING
Trial details
- NCT number
- NCT05141474
- Sponsor
- Vall d'Hebron Institute of Oncology
- Status
- RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-28
- Primary completion
- 2027-01-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.